India, April 14 -- Shares of Verve Therapeutics, Inc. (VERV) were gaining around 30 percent in the pre-market activity on the Nasdaq, after the clinical-stage company focused on genetic medicines for cardiovascular disease announced Monday positive initial data from the Heart-2 Phase 1b clinical trial of VERVE-102.
In its statement, the company noted that its Heart-2 Phase 1b clinical trial is evaluating patients with heterozygous familial hypercholesterolemia or HeFH and/or premature coronary artery disease or CAD, two populations that require deep and durable reductions of low-density lipoprotein cholesterol or LDL-C levels in the blood.
VERVE-102 is a novel, in vivo, investigational base editing medicine designed to be a single-course ...